Enhanced Expression of Thrombospondin–1 and Hypovascularity in Human Cholangiocarcinoma
Open Access
- 30 December 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 28 (6), 1512-1517
- https://doi.org/10.1002/hep.510280610
Abstract
Cholangiocarcinoma (CCC) is relatively hypovascular, in contrast to hepatocellular carcinoma (HCC), which is often highly vascular. We investigated if the diminished vascularity of CCC is related to altered expression of thrombospondin–1 (TSP–1), an antiangiogenic factor, and/or vascular endothelial growth factor (VEGF), a potent angiogenic factor, comparing the relationships with those of high– and low–vascular HCC. We also investigated the relationship between the mutation of the p53 gene and TSP–1 expression or VEGF expression. Northern blot analysis and immunohistochemical staining were performed on surgically resected human CCC and HCC. The ratios of TSP–1 mRNA level in cancer cells versus adjacent noncancerous cells (T/N ratios) were significantly higher in CCC (n = 11) than in HCC with high vascularity (n = 15). In contrast, T/N ratios of VEGF mRNA level in CCC (n = 11) were comparable with those in HCC with low vascularity (n = 5). In CCC, the cancer cells and fibroblasts were positively stained with anti-TSP–1 antibody. We observed that T/N ratios of VEGF mRNA level, but not those of the TSP–1 mRNA level, were significantly correlated with vascularity in HCC. The relative increase in TSP–1 and the relative decrease in VEGF in tumors compared with normal tissue may underlie the limited angiogenesis of CCC. The p53 gene did not affect the expression of TSP–1 in CCC or VEGF in HCC.This publication has 16 references indexed in Scilit:
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- The role of thrombospondin‐1 in tumor progression and angiogenesisBioEssays, 1996
- Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis.Proceedings of the National Academy of Sciences, 1995
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- The role of vascular endothelial growth factor in pathological angiogenesisBreast Cancer Research and Treatment, 1995
- Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1Science, 1994
- Vascular permeability factor (VPF, VEGF) in tumor biologyCancer and Metastasis Reviews, 1993
- Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activityThe Journal of cell biology, 1993
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth FactorScience, 1992